Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study

Hippokratia

Volumn 16, Issue 1, 2012, Pages 40-45

  Aktoz, T ^a   Durmus Altun, G ^a   Usta, U ^a   Torun, N ^a   Ergulen, A ^a   Atakan, I H ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Amifostine; Radioiodine therapy; Renal toxicity

Indexed keywords

AMIFOSTINE; IODINE 131;

ABLATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; KIDNEY TUBULE DAMAGE; NEPHROTOXICITY; NONHUMAN; RADIOACTIVITY; RADIOISOTOPE THERAPY; RAT; RENAL PROTECTION; THERAPY EFFECT; TOXICITY TESTING;

EID: 84855467291     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. 2000 report to the general assembly with annexes. Vienna: United Nations; 2001.
2. Hoefnagel CA. Radionuclide cancer therapy. Ann Nucl Med. 1998; 12: 61-70.
3. Ambrosetti MC, Colato C, Dardano A, Monzani F, Ferdeghini M. Radioiodine ablation: when and how. Q J Nucl Med Mol Imaging. 2009; 53: 473-481.
4. Thyroid Cancer. A Comprehensive Guide to Clinical Management. Side Effects of 131I for Ablation and Treatment of Well-Differentiated Thyroid Carcinoma. Douglas Van Nostrand and John Freitas. Edited by: L. Wartofsky and D. Van Nostrand. Humana Press Inc., Totowa, NJ.
5. Rolleman EJ, Forrer F, Bernard B, Bijster M, Vermeij M, Valke-ma R, et al. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177LuDOTA0,Tyr3] octreo-tate. Eur J Nucl Med Mol Imaging. 2007; 34: 763-771.
6. Driver I, Packer S. Radioactive waste discharge quantities for patients undergoing radioactive iodine therapy for thyroid carcinoma. Nucl Med Commun. 2001;22:1129-1132.
7. Chatal JF, Hoefnagel CA. Radionuclide therapy. Lancet. 1999; 354: 931-935.
8. Levi M, Knol JA, Ensminger WD, DeRemer SJ, Dou C, Lunte SM, et al. Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys. Drug Metab Dispos. 2002; 30: 1425-1430.
9. Kaldir M, Cosar-Alas R, Cermik TF, Yurut-Caloglu V, Saynak M, Altaner S, et al. Amifostine use in radiation-induced kidney damage. Preclinical evaluation with scintigraphic and histo-pathologic parameters. Strahlenther Onkol. 2008; 184: 370-375.
10. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radio-nuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2010; 37: 1018-1031.
11. Caloglu M, Yurut-Caloglu V, Durmus-Altun G, Oz-Puyan F, Us-tun F, Cosar-Alas R, et al. Histopathological and scintigraphic comparisons of the protective effects of L-carnitine and amifos-tine against radiation-induced late renal toxicity in rats. Clin Exp Pharmacol Physiol. 2009; 36: 523-530.
12. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999; 141: 443-457.
13. Spitzweg C, Dutton CM, Castro MR, Bergert ER, Goellner JR, Heufelder AE, et al. Expression of the sodium iodide symporter in human kidney. Kidney Int. 2001; 59: 1013-1023.
14. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999; 17: 3333-3355.
15. Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C, et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys. 1986; 12: 1501-1504.
16. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 2007; 12: 738-747.
17. Leach JK, Black SM, Schmidt-Ullrich RK, Mikkelsen RB. Ac tivation of constitutive nitric-oxide synthase activity is an early signaling event induced by ionizing radiation. J Biol Chem. 2002; 277: 15400-15406.
18. Conklin KA. Cancer chemotherapy and antioxidants. J Nutr. 2004; 134: 3201-3204.
19. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol. 1999; 26: 72-81.
20. Weichert-Jacobsen KJ, Bannowski A, Küppers F, Loch T, Stöckle M. Direct amifostine effect on renal tubule cells in rats. Cancer Res. 1999; 59: 3451-3453.
21. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000; 18: 3339-3345.
22. Uzunoglu S, Karagol H, Ozpuyan F, Cosar R, Cicin I, Yurut- caloglu V, et al. Protective effect of L-carnitine versus amifos- tine against cisplatin-induced nephrotoxicity in rats. Med Oncol. 2010 Dec 8. [Epub ahead of print]
23. Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson's dis ease. Parkinsons Dis. 2010 Dec 20; 2011: 658083.
24. Aksu B, Umit H, Kanter M, Guzel A, Aktas C, Civelek S, et al. Effects of methylene blue in reducing cholestatic oxidative stress and hepatic damage after bile-duct ligation in rats. Acta Histochem. 2010; 112: 259-269.